AG
BCRX icon

Algert Global’s BioCryst Pharmaceuticals BCRX Stock Holding History

Algert Global’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-713,088
Closed -$5.41M – 1148
2025
Q3 		$5.41M Sell
713,088
-289,722
-29% -$2.41M 0.09% 384
2025
Q2 		$8.99M Buy
1,002,810
+42,753
+4% +$398K 0.19% 154
2025
Q1 		$7.2M Buy
960,057
+234,752
+32% +$1.89M 0.18% 164
2024
Q4 		$5.45M Buy
725,305
+209,096
+41% +$1.59M 0.13% 261
2024
Q3 		$3.92M Buy
516,209
+163,076
+46% +$1.24M 0.11% 330
2024
Q2 		$2.18M Buy
353,133
+55,311
+19% +$305K 0.07% 444
2024
Q1 		$1.51M Sell
297,822
-38,943
-12% -$219K 0.06% 503
2023
Q4 		$2.02M Buy
336,765
+129,670
+63% +$751K 0.08% 415
2023
Q3 		$1.47M Sell
207,095
-84,461
-29% -$607K 0.07% 467
2023
Q2 		$2.05M Buy
291,556
+30,570
+12% +$245K 0.09% 376
2023
Q1 		$2.18M Buy
260,986
+103,042
+65% +$992K 0.1% 314
2022
Q4 		$1.81M Buy
157,944
+60,817
+63% +$758K 0.1% 325
2022
Q3 		$1.22M Buy
97,127
+19,139
+25% +$246K 0.07% 455
2022
Q2 		$825K Buy
77,988
+9,874
+14% +$102K 0.06% 558
2022
Q1 		$1.11M Buy
68,114
+48,058
+240% +$771K 0.07% 482
2021
Q4 		$278K Hold
20,056
– – 0.03% 760
2021
Q3 		$288K Buy
+20,056
New +$316K 0.04% 774

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Algert Global's BCRX Position: Q4 2025 in Review

Algert Global sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 713,088 shares — an estimated $5.41M sold.

Algert Global first reported a position in BCRX in Q3 2021 and held it in 17 quarters. The position peaked at $8.99M in Q2 2025. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Algert Global reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Algert Global sold 713,088 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $5.41M.
  • Algert Global first reported a position in BioCryst Pharmaceuticals in Q3 2021 and held it in 17 quarters.
  • Algert Global's BioCryst Pharmaceuticals position peaked at $8.99M in Q2 2025.
  • 272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Algert Global's 13F filing for Q4 2025, filed 17 Feb 2026.